Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Derick Petrie

Physician Assistant, Medical Houma, LA Physician Assistant

NPI 1538559927 CMS profile 11129190

928 School St, Houma, LA 70360

Open in the dashboard

General payments

$3,594

219 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Derick Petrie of Houma, LA is reported in the CMS Open Payments database as having received $3,594 across 219 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $633 36
2024 General $811 47
2023 General $816 48
2022 General $739 48
2021 General $595 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Derick Petrie
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Derick Petrie were reported at $633. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Derick Petrie Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $595 $156 $41–$563 $132
2022 $739 $185 $55–$649 $149
2023 $816 $199 $58–$717 $160
2024 $811 $206 $62–$740 $164
2025 $633 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $751 47 payments
  2. Novo Nordisk Inc $414 25 payments
  3. AstraZeneca Pharmaceuticals LP $411 26 payments
  4. Lilly USA, LLC $371 22 payments
  5. Esperion Therapeutics, Inc. $239 15 payments
  6. GlaxoSmithKline, LLC. $189 9 payments
  7. Tolmar, Inc. $169 9 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $144 9 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $118 8 payments
  10. Corium, Inc. $112 6 payments
  11. Other $676 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,594 219 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $455 30 payments
  2. Ozempic $396 24 payments
  3. RYBELSUS $340 21 payments
  4. QULIPTA $272 16 payments
  5. NEXLETOL $239 15 payments
  6. FARXIGA $225 14 payments
  7. MOUNJARO $223 13 payments
  8. TRELEGY ELLIPTA $189 9 payments
  9. XIFAXAN $118 8 payments
  10. TRULICITY $114 7 payments
  11. Other $1,999 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

219 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record